"Apomorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.
| Descriptor ID |
D001058
|
| MeSH Number(s) |
D03.132.098.038.290 D03.633.100.531.085.030.290 D03.633.400.095.290
|
| Concept/Terms |
Apomorphine Hydrochloride, Anhydrous- Apomorphine Hydrochloride, Anhydrous
- Anhydrous Apomorphine Hydrochloride
- Hydrochloride, Anhydrous Apomorphine
- Apomorphine Hydrochloride Anhydrous
- Anhydrous, Apomorphine Hydrochloride
- Hydrochloride Anhydrous, Apomorphine
Apomorphine Hydrochloride- Apomorphine Hydrochloride
- Hydrochloride, Apomorphine
- Apomorphine Hydrochloride, Hemihydrate
- Hemihydrate Apomorphine Hydrochloride
- Hydrochloride, Hemihydrate Apomorphine
|
Below are MeSH descriptors whose meaning is more general than "Apomorphine".
Below are MeSH descriptors whose meaning is more specific than "Apomorphine".
This graph shows the total number of publications written about "Apomorphine" by people in this website by year, and whether "Apomorphine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Apomorphine" by people in Profiles.
-
On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med. 2021 Sep; 133(7):721-727.
-
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005 May; 20(5):523-39.
-
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord. 2005; 20 Suppl 11:S30-7.
-
Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology. 2000 Jan 25; 54(2):458-62.
-
Clozapine fails to prevent the development of haloperidol-induced behavioral hypersensitivity in a cotreatment paradigm. Eur J Pharmacol. 1990 Aug 02; 184(1):43-53.
-
Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity. Pharmacol Biochem Behav. 1990 Feb; 35(2):291-300.
-
Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation. Life Sci. 1988; 42(22):2207-15.
-
Effects of dopamine antagonists and apomorphine on regional energy metabolism in rat CNS. Clin Neuropharmacol. 1987 Jun; 10(3):247-60.
-
The effect of thioridazine on haloperidol induced behavioral hypersensitivity. Life Sci. 1986 May 12; 38(19):1707-14.
-
L-5-HTP-induced myoclonic jumping behavior in guinea pigs: an update. Adv Neurol. 1986; 43:509-17.